Home › Merck Statement Regarding CUBICIN Patent Litigation
 

Keywords :   


Merck Statement Regarding CUBICIN Patent Litigation

2014-12-09 14:11:00| Merck.com - Corporate News

Dateline City: KENILWORTH, N.J. Company Reaffirms Transaction To Proceed as Planned; Expected to Close in First Quarter of 2015 KENILWORTH, N.J.--(BUSINESS WIRE)--Merck, known as MSD outside the United States and Canada, issued the following statement regarding the decision of the U.S. District Court for the District of Delaware. The decision, which upheld the patent for CUBICIN that expires on June 15, 2016 and invalidated four others, is subject to appeal. Language: English Contact: MerckMedia:Lainie Keller, 908-236-5036orSteve Cragle, 908-740-1801orInvestors:Joe Romanelli, 908-740-1986orJustin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: statement patent litigation merck

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
05.10Hurricane Leslie Graphics
05.10Hurricane Leslie Forecast Discussion Number 11
05.10Hurricane Leslie Wind Speed Probabilities Number 11
05.10Hurricane Leslie Public Advisory Number 11
05.10Summary for Hurricane Leslie (AT3/AL132024)
05.10Hurricane Leslie Forecast Advisory Number 11
05.10Hurricane Kirk Graphics
05.10Hurricane Kirk Forecast Discussion Number 23
More »